← brief for 2026-11-04 · Slowing decline
Formononetin as a Natural Product-Derived Candidate for Diabetic Microvascular Complications: Mechanistic Evidence, Pharmacokinetics, Formulation Strategies, and Translational Barriers.
Key takeaways
This review looks at a plant compound called formononetin. It suggests the compound may protect blood vessels in animals and cells. It is not tested in people yet.
Who did this work
Gao X (The College of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, People's Republic of China.) · Zhang Y (The College of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, People's Republic of China.) · Zheng Y (The College of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, People's Republic of China.) · Qiao L (The College of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, People's Republic of China.) · Liu X (Senior Department of Nephrology, Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing, 100853, People's Republic of China.) · Yang S (Senior Department of Nephrology, Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing, 100853, People's Republic of China.) · Chen X (The College of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, People's Republic of China.) · Xiao Y (Senior Department of Nephrology, Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing, 100853, People's Republic of China.) · Wang X (Senior Department of Nephrology, Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing, 100853, People's Republic of China.) · Liu R (Senior Department of Nephrology, Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing, 100853, People's Republic of China.) · Dong Z (Senior Department of Nephrology, Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing, 100853, People's Republic of China.) · Wang Q (Senior Department of Nephrology, Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing, 100853, People's Republic of China.)
Source
Paper · Europe PMC, CKD · 2026-10-28
https://doi.org/10.2147/dddt.s623611